<ѻýҕl>'Unparalleled Times' in Hematology, but Workforce Issues Persistѻýҕl> "This is the most exciting time ever" to be a hematologist, says ASH President Jane Winter, MD Sep 26, 2022 video
<ѻýҕl>What's on Tap at the Society of Hematologic Oncology's 10th Annual Meetingѻýҕl> Emphasis on novel biological approaches in treating patients with hematologic malignancies Sep 26, 2022
<ѻýҕl>How a Dedicated Bone Marrow Biopsy Clinic Eased Wait Timesѻýҕl> VA center in Cleveland got program up and running in about a month Sep 19, 2022
<ѻýҕl>CAR-T Therapy Effective in Youngest Kids With ALLѻýҕl> Analysis shows safety and outcomes equivalent to those reported in older children Sep 08, 2022
<ѻýҕl>Jane Fonda's Non-Hodgkin Lymphomaѻýҕl> The award-winning actress opened up about her latest health news Sep 06, 2022
<ѻýҕl>Bispecific Antibody Active in Heavily Treated Multiple Myelomaѻýҕl> Responses in 60% of patients who had received a median of five prior lines of therapy Aug 30, 2022
<ѻýҕl>Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomesѻýҕl> Overall response rates were 67% with decitabine, 48% with azacitidine Aug 22, 2022
<ѻýҕl>PK Modulator Shows Promise in Thalassemiaѻýҕl> In small study, mitapivat increased hemoglobin in 80% of non-transfusion-dependent patients Aug 17, 2022
<ѻýҕl>Mandy Moore's Immune Thrombocytopenic Purpuraѻýҕl> What does it mean for the pregnant pop singer/actress? Aug 10, 2022
<ѻýҕl>Experts Warn of Physical, Mental Health Effects of Extreme Heatѻýҕl> Children, people with sickle cell disease, and outdoor workers are particularly at risk Aug 05, 2022
<ѻýҕl>Pneumococcal Vax Slashed Deadly Sickle-Cell Complication in Kidsѻýҕl> Cumulative ACS reduction of 41% since implementation of 13-valent vaccine, French study finds Aug 02, 2022
<ѻýҕl>'Rogue' Online Pharmacies Are Dispensing Cancer Drugsѻýҕl> Shady sites with little oversight are selling imatinib for much less than U.S. retail price Jul 29, 2022
<ѻýҕl>Breast Implant-Related Lymphoma More Common Than Reportedѻýҕl> Contemporary data suggest at least a twofold higher case rate as compared with FDA estimates Jul 21, 2022
<ѻýҕl>Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphomaѻýҕl> More than half of patients achieved complete responses with lisocabtagene maraleucel Jul 18, 2022
<ѻýҕl>Blood Viscosity Enters the Equation in COVID Mortalityѻýҕl> Its association with death may be unrelated to inflammation Jul 18, 2022
<ѻýҕl>Bone Marrow Biopsy Value Limited in Follicular Lymphoma Response Assessmentѻýҕl> Information useful in fewer than 1% of patients with untreated disease Jul 10, 2022
<ѻýҕl>Zanubrutinib Wins in First-Line CLL for Older Patientsѻýҕl> The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial Jul 08, 2022
<ѻýҕl>FDA Warns of Increased Mortality Risk With Duvelisibѻýҕl> Drug approved for adults with CLL/SLL Jul 01, 2022
<ѻýҕl>Kidney Failure May Drive COVID Deaths in People With Sickle Cell Traitѻýҕl> COVID-19 severity strongly linked with sickle cell anemia as well Jun 27, 2022
<ѻýҕl>Brentuximab Vedotin Boosts Survival in Untreated Hodgkin Lymphomaѻýҕl> ECHELON-1 analysis showed 41% mortality risk reduction versus standard treatment Jun 21, 2022
<ѻýҕl>Studies Reinforce Prognostic Role for Circulating Tumor Cells in Myelomaѻýҕl> At higher levels, different cutoffs show at least a doubling of PFS, OS hazard ratios Jun 13, 2022
<ѻýҕl>FDA Panel Backs Gene Tx for Degenerative Brain Disorder in Kidsѻýҕl> Advisers unanimously recommend approval for pediatric ALD patients without HLA-matched donors Jun 10, 2022
<ѻýҕl>Myeloma Trial Supports 'Personalized Approach' to Upfront Transplantѻýҕl> DETERMINATION confirms benefit in triple-therapy setting, but suggests timing can be tailored Jun 06, 2022
<ѻýҕl>Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphomaѻýҕl> Significantly more responses, CRs with zanubrutinib-obinutuzumab versus anti-CD20 drug alone Jun 05, 2022
<ѻýҕl>Brentuximab Vedotin-Chemo Boosts EFS in High-Risk Pediatric Hodgkin Lymphomaѻýҕl> Combo regimen offers "a new standard for front-line therapy," researcher says Jun 04, 2022
<ѻýҕl>Add-On Ibrutinib Boosts PFS in Untreated, Older Mantle-Cell Lymphoma Patientsѻýҕl> BTK inhibitor plus chemoimmunotherapy increased progression-free survival by over 2 years Jun 03, 2022
<ѻýҕl>FDA Pulls Lymphoma Approvals for PI3K Inhibitor Umbralisibѻýҕl> Worse overall survival observed despite improvements in progression-free survival Jun 01, 2022
<ѻýҕl>Unprecedented PFS Improvement in Relapsed Multiple Myelomaѻýҕl> Three-year median with addition of isatuximab to proteasome inhibitor backbone May 26, 2022
<ѻýҕl>Elotuzumab Combination Disappoints in Newly Diagnosed Myelomaѻýҕl> Study failed to replicate positive results seen in relapsed/refractory setting May 11, 2022
<ѻýҕl>Corticosteroids Linked to Pain Events in Patients With Sickle Cell Diseaseѻýҕl> Hospitalization risk for vaso-occlusive episodes four times higher after exposure May 02, 2022
<ѻýҕl>Promising Data for Allo-Transplant After CAR T-Cell Failure in LBCLѻýҕl> Durable responses with no unexpected or prolonged safety issues Apr 27, 2022
<ѻýҕl>Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDSѻýҕl> 1-year relapse-free survival rate of 60% with maintenance therapy after transplant Apr 25, 2022
<ѻýҕl>BTK Inhibitor Shows Potential in Immune Thrombocytopeniaѻýҕl> Across doses, 40% of heavily pretreated patients responded to oral rilzabrutinib Apr 13, 2022
<ѻýҕl>Bispecific Antibody-NK Cell Complex Impresses in Early Hodgkin/NHL Trialѻýҕl> Objective responses in 89% of patients with no CRS, neurotoxicity, or graft-versus-host disease Apr 11, 2022
<ѻýҕl>9/11 Responders More Likely to Carry Genetic Mutations Tied to Cancerѻýҕl> Clonal hematopoiesis seen in 10% of firefighters, medical personnel on the scene after WTC attack Mar 07, 2022
<ѻýҕl>Cancer May Heighten Odds of Guillain-Barre Syndromeѻýҕl> Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
<ѻýҕl>Dear Blood Donors, You've Given Me the Gift of Lifeѻýҕl> I offer my gratitude through acceptance, acknowledgement, and reflection Feb 06, 2022
<ѻýҕl>FDA Concerned About Safety of Lymphoma Drugѻýҕl> Hint of excess mortality in trial of umbralisib/ublituximab prompts public notice Feb 03, 2022
<ѻýҕl>Finally, a 'New Standard' for Severe Aplastic Anemiaѻýҕl> After 3 decades of failures, RACE trial shows superiority of new first-line regimen Jan 05, 2022
<ѻýҕl>Myeloma at Younger Age Shortens Lifespan Despite Lengthy Overall Survivalѻýҕl> Disease characteristics, prognostic factors similar to those of older patients Jan 04, 2022